David Hallal, ElevateBio CEO
May 24, 2023 06:00 AM EDT
Financing
Cell/Gene Tx

El­e­vate­Bio snags the year's largest raise with $401M Se­ries D, plus a re­search part­ner­ship with No­vo

Andrew Dunn

Senior Biopharma Correspondent

Just one day af­ter an RNA start­up an­nounced a $300 mil­lion round, El­e­vate­Bio has tak­en away the record for the in­dus­try’s biggest raise of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times